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Burkholderia cepacia is a pathogen usually causing infection to immunocompromised or hospitalized
patients. It is also associated with infections in patients with underlying lung disease, such as cystic
ﬁbrosis and chronic granulomatous disease. We present a case of B. cepacia bacteremia in a patient with
COPD who was hospitalized due to type II respiratory failure. We speculate that B. cepacia, as a chronic
colonizer, may cause infections in patients with lung disease other than cystic ﬁbrosis. Previous antibiotic
administration may have a role in development of such infections.
 2010 Elsevier Ltd. All rights reserved.1. Introduction
Burkholderia cepacia is a Gram-negative, glucose-non-fermenting,
motile, aerobic bacillus. It exhibits a high nutritional versatility and is
resistant to many antibiotics and disinfectants, including povidone
iodine and chlorhexidine. It was discovered by W.H. Burkholder in
1950 as the etiologic agent of sour skin disease in onions. It is asso-
ciated mainly with infections in patients with underlying lung
disease, such as cystic ﬁbrosis and chronic granulomatous disease, as
well as in immunocompromised individuals, hospitalized patients
and drug addicts.1 We describe a case of bacteremia due to B. cepacia
in a patient who was admitted with type II respiratory failure.
2. Case report
A 67-year-old Caucasian male patient presented with respira-
tory distress at the emergency department. He had a history of
coronary artery disease, chronic obstructive pulmonary disease,
chronic atrial ﬁbrillation, diabetes mellitus under treatment and
Parkinson’s disease.
Physical examination revealed severe dyspnea. He had a reduction
of breath sounds of the bases and ﬁne crackles bilaterally. His respi-
ratory rate was 30 breaths/min and the oxygen saturation was 70%,
which increased to 85% after oxygen administration to 15 lt/min. Hisx: þ30 231 031 0266.
thaiou).
rved.blood pressure was 130/70 mmHg and his heart rate was 130 beats/
min. He had a temperature of 38.5 C. The rest of the physical
examination was unremarkable.
His blood tests showed a white blood cell count (WBC) of 8600/
ml, hemoglobin at 11.7mg/dl, urea at 67mg/dl, creatinine at 1.37mg/
dl and C-reactive protein (CRP) at 6 mg/dl. A thoracic x-ray revealed
bilateral inﬁltrations. Arterial blood gas test showed respiratory
acidosis due to respiratory failure type II; namely pH ¼ 7.29,
pCO2 ¼ 63.9 mmHg, pO2 ¼ 68.4 mmHg, and HCO3 ¼ 31 mEq/lt.
The patient received 4.5 g of iv piperacillin-tazobactam (pip/
tazo) every 8 h (q8h). Due to further deterioration, admission of the
patient to the intensive care unit (ICU) was necessary. In the ICU,
the patient received 600 mg of iv linezolid every 12 h (q12h), and
4.5 g of iv pip/tazo q8h. A CT scan of the thorax was done on day 2
without any signiﬁcant ﬁndings. The patient, although febrile,
started to improve. He was hemodynamically stable and was
deintubated at day 3 of admission. There was a transient deterio-
ration at day 4 with mild tachypnea and ﬁne expiratory basal
wheezing bilaterally. WBC increased at 11400/ml, PCT at 3.87 ng/ml,
and CRP at 11.6 mg/dl. The treatment was enhanced by adding
200 mg iv itraconazole q12h and 75 mg oseltamivir q12h.
Pairs of blood cultures were taken on days 1 and 4; urine
cultures were taken on days 1, 4 and 9; central venous catheter
culture was taken on day 4. All of them were negative. No bron-
choalveolar lavage culture was taken. Stabilization of the respira-
tory function and improvement of the general condition, although
the patient was still febrile, led to the transfer of the patient to the
medical ward on day 10.
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crobials were stopped except pip/tazo. On day 14, there was
a positive pair of blood cultures for B. cepacia, which was taken
on day 10 in the ICU. The bacteriumwas susceptible only to pip/tazo
and ciproﬂoxacin, according to the antibiogram. No extended-
spectrum beta-lactamases (ESBL) testing was done. On day 15, the
patient had fever again, up to 38.4 C, and leukocytosis. An
abdominal CT did not provide any signiﬁcant ﬁndings. Treatment
was modiﬁed by replacing pip/tazo with 400 mg iv ciproﬂoxacin
q8h. A new blood culture yielded B. cepacia, which was susceptible
only to ciproﬂoxacin, ceftazidime, and pip/tazo. Ciproﬂoxacin was
retained. The patient started to defervesce on day 19. He remained
afebrile and asymptomatic until his discharge on day 24. He had
received ciproﬂoxacin for 10 days.
3. Discussion
B. cepacia is a member of a group known as B. cepacia complex.
It comprises 9 different recognized genomovars, including Bur-
kholderia. multivorans, Burkholderia. cenocepacia, Burkholderia. sta-
bilis, Burkholderia. vietnamiensis, Burkholderia. dolosa, Burkholderia.
ambifaria, Burkholderia. anthina, and Burkholderia. pyrrocinia.2
B. cepacia complex may cause “cepacia syndrome” which is a form
of progressive necrotizing pneumonia. It is accompanied by an
acute systemic infection and may often prove fatal.3
The bulk of publications regarding bacteremia due to B. cepacia
refer to patients with cystic ﬁbrosis, to whom it is a chronic colo-
nizer, and immunocompromised patients. Outbreaks may occur
due to contaminated antiseptics, disinfectants, ventilators and
other types of medical equipment. In addition, person-to-person
spread has been documented.
Co-trimoxazole is the drug of choice for the treatment of
infections caused by B. cepacia along with ceftazidime and mer-
openem, alone or in combination with other antibiotics.4 It is
innately resistant to various antimicrobial agents including poly-
myxins, aminoglycosides, chloramphenicol and b-lactams. Mech-
anisms conferring resistance include efﬂux pumps, production of
b-lactamases and other modifying enzymes, as well as modiﬁcation
of antibiotic targets.5,6 These characteristics allow the use of
selective culture media to facilitate B. cepacia isolation. It should
be noted that SHV-12 which is an ESBL was detected in B. cepacia.7
In a case-control study among ICU patients without cystic
ﬁbrosis bacteremia due to B. cepacia was associated with renal
failure requiring dialysis, recent abdominal surgery, bronchos-
copies before the bacterial isolation, tracheostomy, and presence
of a central line before the bacterial isolation.8 In a cohort inclu-
ding patients with B. cepacia bacteremia, the majority had serious
comorbidities including diabetes mellitus, chronic obstructive
pulmonary disease (COPD), malignancy and congestive heart fai-
lure.9 However, no data regarding cystic ﬁbrosis were reported.
Our patient was diabetic, had COPD, and was hospitalized in the
ICU. However, he did not have malignancies, was not transplanted
and was minimally exposed to invasive procedures. Although dia-
betes mellitus may cause impairment of the immune system, it
happens in patients with poor glycemic control.10 This is not the
case for our patient, who had a satisfactory response to antidiabetictreatment. In addition, this was a unique case of B. cepacia isolation
for a long time. No outbreaks were reported either before or after
the isolation, thus ruling out the probability of environmental
contamination or person-to-person transmission.
Regarding treatment, pip/tazo is a broad-spectrum antibiotic,
which is effective against most community or hospital-acquired
pathogens. Although it was appropriate, it failed probably due to
ESBL production. Alternatively, ciproﬂoxacin was used and the
patient was cured after 10 days of treatment. It should be noted that
no ESBL identiﬁcation was performed. However, the antibiogram
pattern was compatible with that of an ESBL producing pathogen.
There were consequent positive blood cultures, which rule out
a probable specimen contamination. No bronchoalveolar lavage
was done.
Patients with COPD have lesions, such as bronchiectasias, which
may be niches for chronic colonizers. Broad-spectrum antibiotics
with good penetration in the pulmonary parenchyma may control
infectious exacerbations of COPD. However, pathogens which are
resistant to such antibiotics may cause opportunistic infections.
Thus, we may speculate that B. cepacia, as a chronic colonizer
with innate resistance to many antibiotics, may cause infections in
patients with lung disease other than cystic ﬁbrosis, such as COPD.
Previous administration of broad-spectrum antibiotics to which
B. cepacia is resistant may have a role in development of such
infections.
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